🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million new cases per year. Particularly high rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has classified it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization represents a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Data and Global Access

According to results published in a prominent scientific publication, the new drug cured the vast majority of cases of the STI. This establishes an equal footing with the typical regimen, which uses two antibiotics. The research enrolled over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have shared optimism. Access to a easy-to-administer therapy like this is described as a "critical tool" for gonorrhoea control. This is considered crucial to lessen the impact of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.